These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27756209)

  • 1. Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania.
    Makubi A; Sasi P; Ngaeje M; Novelli EM; Mmbando BP; Gladwin MT; Makani J
    BMC Med Res Methodol; 2016 Oct; 16(1):140. PubMed ID: 27756209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol.
    Smaldone A; Manwani D; Aygun B; Smith-Whitley K; Jia H; Bruzzese JM; Findley S; Massei J; Green NS
    BMC Pediatr; 2019 Oct; 19(1):354. PubMed ID: 31615480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
    Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
    Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea mobile directly observed therapy versus standard monitoring in patients with sickle cell anemia: a phase 2 randomized trial.
    Sasi P; Makubi A; Sangeda RZ; Ngaeje MY; Mmbando BP; Soka J; Rosano C; Magesa AS; Cox SE; Makani J; Novelli EM
    Commun Med (Lond); 2024 Aug; 4(1):160. PubMed ID: 39122788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
    Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
    JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
    Smaldone A; Findley S; Bakken S; Matiz LA; Rosenthal SL; Jia H; Matos S; Manwani D; Green NS
    Contemp Clin Trials; 2016 Jul; 49():134-42. PubMed ID: 27327779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
    Salvia AC; Figueiredo MS; Braga JA; Pereira DF; Brighenti FL; Koga-Ito CY
    J Oral Pathol Med; 2013 Aug; 42(7):570-5. PubMed ID: 23278631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study protocol for ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness): Using small business partnerships to deliver a scalable and novel hydroxyurea adherence solution to youth with sickle cell disease.
    Walden J; Brown L; Seiguer S; Munshaw K; Rausch J; Badawy S; McGann P; Winkler S; Gonzalez L; Creary S
    PLoS One; 2024; 19(6):e0304644. PubMed ID: 38917111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia.
    Estepp JH; Winter B; Johnson M; Smeltzer MP; Howard SC; Hankins JS
    Pediatr Blood Cancer; 2014 Nov; 61(11):2031-6. PubMed ID: 25132074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
    Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
    Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea treatment of sickle cell anemia in hospital-based practices.
    Ferguson RP; Arun A; Carter C; Walker SD; Castro O
    Am J Hematol; 2002 Aug; 70(4):326-8. PubMed ID: 12214583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia.
    Creary SE; Beeman C; Stanek J; King K; McGann PT; O'Brien SH; Liem RI; Holl J; Badawy SM
    Pediatr Blood Cancer; 2022 Jun; 69(6):e29607. PubMed ID: 35373884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ENHANCE-(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease.
    Creary S; Chisolm DJ; O'Brien SH
    JMIR Res Protoc; 2016 Oct; 5(4):e193. PubMed ID: 27697749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
    Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
    Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea therapy for sickle cell anemia.
    McGann PT; Ware RE
    Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
    Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
    Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Wise Device Technology to Measure Adherence to Hydroxyurea Therapy in Youth With Sickle Cell Disease.
    Ingerski LM; Loew M; Porter JS; Su Y; Zhang H; Hankins JS; Wang WC
    J Pediatr Hematol Oncol; 2021 Jan; 43(1):e19-e25. PubMed ID: 33235145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia.
    Darbari DS; Nouraie M; Taylor JG; Brugnara C; Castro O; Ballas SK
    Eur J Haematol; 2014 Apr; 92(4):341-5. PubMed ID: 24330217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT) efficacy trial: Community health worker support may increase hydroxyurea adherence of youth with sickle cell disease.
    Green NS; Manwani D; Aygun B; Appiah-Kubi A; Smith-Whitley K; Castillo Y; Soriano L; Jia H; Smaldone AM
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30878. PubMed ID: 38321562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.